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Objective. Patients with systemic lupus erythem-
atosus (SLE) have a notable increase in atherothrom-
botic cardiovascular disease (CVD) which is not ex-
plained by the Framingham risk equation. In vitro
studies indicate that type I interferons (IFNs) may play
prominent roles in increased CV risk in SLE. However,
the in vivo relevance of these findings, with regard to the
development of CVD, has not been characterized. This
study was undertaken to examine the role of type I IFNs
in endothelial dysfunction, aberrant vascular repair,
and atherothrombosis in murine models of lupus and
atherosclerosis.
Methods. Lupus-prone New Zealand mixed 2328
(NZM) mice and atherosclerosis-prone apolipoprotein E–
knockout (apoE/) mice were compared to mice lack-
ing type I IFN receptor (INZM and apoE/IFNAR/
mice, respectively) with regard to endothelial vaso-
dilatory function, endothelial progenitor cell (EPC)
function, in vivo neoangiogenesis, plaque development,
and occlusive thrombosis. Similar experiments were
performed using NZM and apoE/ mice exposed to an
IFN-containing or empty adenovirus.
Results. Loss of type I IFN receptor signaling
improved endothelium-dependent vasorelaxation, lipo-
protein parameters, EPC numbers and function, and
neoangiogenesis in lupus-prone mice, independent of
disease activity or sex. Further, acute exposure to IFN
impaired endothelial vasorelaxation and EPC function
in lupus-prone and non–lupus-prone mice. Decreased
atherosclerosis severity and arterial inflammatory infil-
trates and increased neoangiogenesis were observed in
apoE/IFNAR/ mice, compared to apoE/ mice,
while NZM and apoE/ mice exposed to IFN devel-
oped accelerated thrombosis and platelet activation.
Conclusion. These results support the hypothesis
that type I IFNs play key roles in the development of
premature CVD in SLE and, potentially, in the general
population, through pleiotropic deleterious effects on
the vasculature.
Systemic lupus erythematosus (SLE) is associ-
ated with a dramatic increase in atherothrombotic car-
diovascular disease (CVD), which is not explained by the
Framingham risk equation (1–3). To date, no drug has
been proven effective in decreasing CV risk in SLE.
Therefore, it is crucial to establish the key drivers of
vascular insult and atherosclerosis progression in lupus,
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in order to identify effective therapeutic and preventive
targets.
While immune dysregulation may play a major
role in premature CVD in SLE, the etiology of acceler-
ated atherosclerosis in this disease remains unclear.
Nevertheless, in vitro studies from our group and others
indicate that type I interferons (IFNs) could play crucial
roles in CVD development in SLE. This may be due to
the capacity of IFN, and potentially other type I IFNs,
to impair vascular repair (4), enhance foam cell forma-
tion (5), and activate platelets through changes in the
megakaryocyte transcriptome (6). IFN, another type I
IFN, may promote atherosclerosis by promoting macro-
phage recruitment to arteries (7).
IFN leads to an imbalance of vascular damage
and repair by impairing the phenotype and function of
bone marrow (BM)–derived endothelial progenitor cells
(EPCs) (4) and by inducing transcriptional repression of
angiogenic factors (8). However, while a prominent role
for IFN in lupus pathogenesis and clinical manifesta-
tions is supported by human and murine studies (9), it
is unclear if type I IFNs are major inducers of vascular
damage in vivo in SLE.
Increased endothelial cell (EC) damage in SLE is
associated with perturbations in endothelium-dependent
vasorelaxation (10), an established predictor of athero-
sclerosis progression (11). While most mouse strains
(including lupus-prone mice) are resistant to diet-
induced atherosclerosis (12), endothelial dysfunction
develops in various models, including the lupus-prone
(NZBNZW)F1 strain (13). Therefore, impairments in
endothelium-dependent vasorelaxation can be used as a
surrogate marker of vascular damage in murine models.
In this study, we demonstrate a prominent in vivo
role of type I IFNs in the development of endothelial
dysfunction, aberrant vascular repair, and atherothrom-
bosis in murine models of lupus and atherosclerosis.
MATERIALS AND METHODS
Mice. Breeding pairs of lupus-prone NZM2328
(NZM) and NZM2328 IFNR/ (INZM) mice were a
gift from Dr. Chaim Jacob (University of Southern Cali-
fornia, Los Angeles). Female mice were killed at 20 weeks
of age (before proteinuria onset) or 30 weeks of age (after
onset of significant proteinuria/active lupus). Male NZM
and INZM mice were killed at 20, 30, or 40 weeks of age.
Breeding pairs of IFNR/ mice (14,15) were a gift from
Dr. H. W. Virgin (Washington University, St. Louis, MO).
The apoE/IFNR/ mice were generated by backcross-
ing apoE/ mice (The Jackson Laboratory) with IFNR/
mice, both on the C57BL/6 background, to generate double
heterozygotes, followed by backcrossing the offspring back to
the apoE/ background. The genotype was confirmed by
polymerase chain reaction. Protocols were approved by the
University of Michigan’s Committee on Use and Care of
Animals. Mice were bred and housed in a specific pathogen–
free barrier facility at the University of Michigan. Proteinuria
was assessed using Uristix 4 (Siemens).
Adenovirus administration. Murine IFN-expressing
adenovirus (AdIFN) was synthesized as previously described
(16). Empty adenovirus control (AdControl) was obtained
through the University of Michigan’s Vector Core. Adenovirus
was administered to 12-week-old NZM and BALB/c mice and
to 8-week-old apoE/ mice, at 3–4  109 particles in 100 l
phosphate buffered saline (PBS), via tail vein injection. Injec-
tion efficacy was assessed by spleen size and levels of type I
IFN–regulated genes (Mx1, Mcp1, Irf7, Ip10, and Isg15) in
spleen and BM (data not shown), since IFN levels were not
reliably detected in the serum by enzyme-linked immunosor-
bent assay (ELISA), as previously reported (16,17).
Assessment of endothelium-dependent vasorelaxation.
Endothelium-dependent vasorelaxation was assessed as previ-
ously described by our group (13,18). Mouse aortas were cut
into 2-mm–long rings, which were mounted in a myograph
system (DMT-USA). Concentration-response curves were
obtained after contracting vessels with phenylephrine (106
moles/liter), followed by acetylcholine (ACh; 107 moles/liter)
to test endothelial integrity. Vessels were recontracted with
phenylephrine at 75% maximum response concentration
(EC75) and allowed to reach a stable plateau in the contrac-
tion. ACh (1010–105 moles/liter) was added cumulatively to
examine endothelium-dependent relaxation, expressed as per-
cent phenylephrine EC75 contraction (18).
Quantification of EPC number and differentiation.
Mononuclear fractions from BM and spleen single-cell suspen-
sions or from whole blood were obtained by Histopaque 1083
(Sigma) gradient centrifugation. Red blood cells (RBCs) were
lysed with RBC lysis buffer (BioLegend). Approximately 1–5
106 BM and spleen cells or 2–5  105 peripheral blood
mononuclear cells were incubated with monoclonal antibodies
against murine CD34, vascular endothelial growth factor re-
ceptor 2 (VEGFR-2), Sca-1, CD117, CD3, CD19, and CD45
(all from eBioscience) and murine lineage depletion cocktail
(Miltenyi Biotec) for 30 minutes on ice, followed by incuba-
tion with Pacific Blue–labeled annexin V (BioLegend).
Fluorescence-activated cell sorting (FACS) was performed
with FACSCalibur (BD Biosciences) or CyAn (Beckman),
followed by analysis with FlowJo (Tree Star). EPCs were
quantified as CD34VEGFR-2Lin or Sca-1CD117Lin,
as previously described (13,19,20).
BM or spleen mononuclear cell fractions were plated
onto fibronectin-coated plates (1  106 cells/cm2) in EGM-2
BulletKit media (Lonza) with 5% heat-inactivated fetal bovine
serum. On day 7, cells were incubated with fluorescein isothio-
cyanate (FITC)–conjugated Bandeiraea (Griffonia) simplicifo-
lia lectin 1 (BS-1; Vector) and Dil-labeled acetylated low-
density lipoprotein (LDL; Biomedical Technologies) for 4
hours, then analyzed by fluorescence microscopy (Olympus
IX70). Images were acquired using a CoolSNAP HQ2 mono-
chrome camera (Photometrics) and MetaMorph Premier ver-
sion 6.3 acquisition software (Molecular Devices). Final pro-
cessing was performed with Adobe Photoshop CS2. Cells
costaining with BS-1 and acetylated LDL were considered to
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be mature ECs and were quantified in 5–6 random fields per
well using CellC software.
EPCs were quantified in mouse aorta sections using
rabbit anti-mouse CD31 (1:20), rat anti-mouse Sca-1 (1:200)
(both from Abcam), and appropriate isotype controls (eBio-
science). Secondary antibodies included Alexa Fluor 488–
conjugated goat anti-rat IgG and Alexa Fluor 555–conjugated
donkey anti-rabbit IgG (both from Invitrogen). Nuclei were
counterstained by DAPI (Invitrogen). Images were acquired
with an Olympus BX51A fluorescence microscope.
In vivo Matrigel plug angiogenesis assay. Matrigel
plug assays were performed as previously described (21).
Growth factor–reduced Matrigel (500 l; Becton Dickinson)
containing 20 nM basic fibroblast growth factor (R&D Sys-
tems) was injected subcutaneously, and mice were killed 7 days
postinjection. Plugs were excised, and angiogenesis was mea-
sured using the 3,3,5,5-tetramethylbenzidine method (22) to
quantify hemoglobin, standardized to plug weight, as an indi-
rect measure of new blood vessel formation. In some experi-
ments, a portion of the plug was frozen in OCT medium and
stained with polyclonal rabbit anti–von Willebrand factor
(DakoCytomation) or rabbit IgG, followed by FITC-conjugated
anti-rabbit IgG (Invitrogen). Nuclear staining was performed
with DAPI. Images were acquired with an Olympus fluores-
cence microscope.
Carotid arterial thrombosis. Mice were subjected to
photochemical injury of the right carotid artery by rose bengal
dye, as previously described (23). Mice were anesthetized and
placed under a dissecting microscope (Nikon SMZ2-T; Mager
Scientific), and the right carotid artery was isolated. A Doppler
flow probe (Transonic) was applied, and rose bengal dye
(Fisher Scientific) diluted in PBS was injected into the tail vein
(50 mg/kg). A 1.5-mW green light laser (540 nm) (Melles
Griot) was applied to the desired site of injury, from a distance
of 6 cm, and vessel flow was monitored until occlusive throm-
bosis occurred, defined as flow cessation for at least 10
minutes.
Platelet activation assessment. Serum soluble P-selectin
level was quantified by ELISA (R&D Systems). Leukocyte–
platelet aggregates (Gr-1CD61 cells) and platelet
P-selectin level were quantified by FACS (CyAn), after 50 l
of blood was added to 100 l of heparin (10,000 IU/ml; Sigma),
and incubated with fluorochrome-conjugated antibodies
against murine CD61, CD62P, and Gr-1 (all from eBiosci-
ence), followed by RBC lysis and analysis by FlowJo.
Atherosclerosis quantification and immunohistochem-
ical analysis of mouse aortic valves. Animals were fed a
Western diet (Harlan) for10 weeks, starting at 8–10 weeks of
age. At euthanasia, mice were perfused with saline, carcasses
were fixed in formalin, and arterial trees were dissected and
placed in 70% ethanol, then stained with oil red O (Sigma).
The surface area occupied by atherosclerosis was quantified
at the aortic arch and major branches using Image-Pro Plus
software (Media Cybernetics) and expressed as percentage of
total surface area examined, as previously described (24).
Rat anti-mouse F4/80 (1:200) and rabbit anti-mouse
CD3 (1:100) (both from Abcam) staining was followed by
peroxidase-conjugated AffiniPure goat anti-rat IgG (HL) or
peroxidase-conjugated donkey anti-rabbit IgG, respectively
(1:200; Jackson ImmunoResearch). Images were visualized
using a DAB-Plus Substrate Kit (Invitrogen). Digital images
were obtained with a DP71 camera mounted on an Olympus
BX51B microscope. Quantification of F4/80 and CD3 staining
area was performed using ImageJ software (NIH Image,
National Institutes of Health; online at http://rsbweb.nih.gov/
ij/).
High-density lipoprotein (HDL) oxidation assessment.
HDL was isolated from mouse plasma by buoyant density
ultracentrifugation as previously described (25). HDL protein
was precipitated with ice-cold trichloroacetic acid and delipi-
dated with water/methanol/water-washed diethyl ether. The
protein pellet was subjected to acid hydrolysis using 4N
methane sulfonic acid supplemented with 1% benzoic acid at
110°C for 24 hours, after addition of isotopically labeled
internal standards. Amino acids were isolated from hydrolysate
with Supelclean ENVI-Chrom P columns (Supelco) as previ-
ously described (26). Liquid chromatography–electrospray ion-
ization tandem mass spectrometry using multiple reaction
monitoring (27) was used to quantify 3-nitrotyrosine. The ratio
of peak areas of the analyte multiple reaction monitoring
transitions versus corresponding isotopically labeled internal
standard was used to calculate 3-nitrotyrosine and tyrosine
content. Results were normalized to tyrosine protein content,
the precursor of 3-nitrotyrosine.
Statistical analysis. Results are presented as the
mean  SEM. Statistical analysis was performed using Stu-
dent’s t-test, and data were analyzed using GraphPad Prism
software version 5. The median effective concentration (EC75)
for agent-induced vasorelaxation was calculated by nonlinear
regression analysis (GraphPad Prism version 5).
RESULTS
Improved endothelial vasorelaxation and EPC
numbers in the absence of type I IFN signaling in
lupus-prone NZM mice. We previously reported that
female lupus-prone NZB  NZW mice have impaired
endothelial and EPC function, and decreased tissue and
circulating EPCs. This impairment correlates with en-
hanced expression of type I IFN–responsive genes in
EPC compartments (13). To directly address the puta-
tive role of type I IFNs in EC and EPC function in lupus,
we examined NZM mice, which show similar lupus
disease progression to the NZB  NZW strain from
which they were derived (28). NZM mice were com-
pared to NZM mice lacking type I IFN receptor (INZM
mice). When the endothelium-dependent response of
thoracic aortas to ACh was quantified, 30-week-old
female INZM mice displayed significant improvements
in vasorelaxation compared to age- and sex-matched
NZM mice (Figure 1A).
Compared to female NZM mice, 30-week old
female INZM mice displayed increased numbers of BM
and circulating EPCs (Figure 1B). (Additional results
are available online at http://deepblue.lib.umich.edu/.)
Younger (20-week-old) INZM female mice displayed
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increases in spleen EPC numbers compared to NZM
mice (P  0.05; data not shown), while no changes were
observed in their BM or blood EPC numbers. In contrast
to our previous findings in NZB  NZW mice (13), we
did not observe differences in EPC apoptosis upon loss
of type I IFN signaling in female NZM mice (data not
shown).
The beneficial effects on endothelial function
and EPC numbers observed in INZM mice could be a
direct result of blocking type I IFN signaling or second-
ary to abrogation of lupus development, including renal
disease, in INZM mice (29). To determine if type I IFNs
directly impair vasorelaxation in murine models of lu-
pus, independent of disease activity, we performed
similar experiments in male NZM and INZM mice, since
neither of them develop significant SLE features. Simi-
lar to autologous female mice, 40-week-old male INZM
mice demonstrated significant increases in endothelium-
dependent vasorelaxation and spleen EPC numbers
compared to age- and sex-matched NZM mice (Figures
1C and D), with no changes in EPC apoptosis. There
were no significant differences between the male groups
at younger ages (20 weeks and 30 weeks of age; data not
shown). These results indicate that type I IFNs signifi-
cantly modulate endothelium-dependent vasorelaxation
and EPC numbers in lupus-prone mice, independently
of disease activity or sex.
Improved EPC function and in vivo neoangiogen-
esis in the absence of type I IFN signaling in lupus-
prone NZM mice. We previously reported that EPCs
from NZB  NZW mice and lupus patients display
decreased capacity to differentiate into mature ECs
when exposed to proangiogenic stimulation (4,13). Con-
firming a role for type I IFNs in impairing endothelial
differentiation, EPCs from female INZM mice displayed
increased ability to differentiate into mature ECs when
compared to those from age-matched female NZM
mice. This improvement was observed by 20 weeks of
age, before evidence of active lupus, and was maintained
after florid disease development at 30 weeks of age
(Figure 2A). These findings were confirmed in male
mice, as BM EPCs from 40-week old (but not 30-week
Figure 1. Improved endothelial function and increased endothelial progenitor cell (EPC) numbers in the absence of type I interferon signaling in
lupus-prone NZM2328 (NZM) mice. A, Increased aortic endothelium-dependent vasorelaxation in response to acetylcholine (ACh) in 30-week-old
female NZM IFNAR/ (INZM) mice compared to age- and sex-matched NZM mice. B, Increased numbers of bone marrow (BM) and blood (Bld)
EPCs in 30-week-old female INZM mice compared to age- and sex-matched NZM mice. C, Improved endothelium-dependent vasorelaxation in
40-week-old male INZM mice compared to age and sex-matched NZM mice. D, Increased numbers of spleen (Spl) EPCs in 40-week-old male INZM
mice compared to age- and sex-matched NZM mice. Values are the mean  SEM (n  8 mice per group in A, 13 mice per group in B, and 6 mice
per group in C and D).   P  0.05;   P  0.01;   P  0.001, versus INZM mice in A and C and versus NZM mice in B and D. EC75 
75% maximum response concentration.
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old) INZM mice displayed significant increases in dif-
ferentiation into mature ECs compared to cells from
age-matched NZM mice (Figure 2B and data not shown).
In vivo Matrigel plug assays were performed to
assess the effects of type I IFNs on the capacity of
lupus-prone mice to form new blood vessels. Compared
to age- and sex-matched NZM mice, female INZM mice
(25–30 weeks old) and male INZM mice (30–40 weeks
old) displayed significant increases in in vivo neoangio-
genesis (Figures 2C and D). These results demonstrate
that type I IFNs promote decreased angiogenesis in
lupus-prone mice, independent of disease activity or sex.
Worsening of endothelium-dependent vasorelax-
ation and EPC differentiation after acute exposure to
IFN in murine lupus. Since lack of type I IFN signaling
significantly improved endothelial and EPC function in
lupus-prone mice, we explored whether acute exposure
to enhanced levels of IFN, such as those seen in acute
infections (30) or lupus flares (31), promoted the oppo-
site effects. Compared to mice that received AdControl,
female NZM mice that received systemic AdIFN at
12 weeks of age displayed significant decreases in
endothelium-dependent vasorelaxation by 3 weeks
postinjection. AdIFN administration did not impact
EPC numbers or apoptosis (data not shown). However,
EPC differentiation into mature ECs was significantly
reduced in mice that received AdIFN compared to
those that received AdControl (Figure 3A).
Similar to the NZB  NZW parental strain (16),
AdIFN administration led to acceleration of nephritis
onset. (Details on the clinical and demographic charac-
teristics of the mouse strains are available online at
http://deepblue.lib.umich.edu/.) To establish whether
the endothelial defects observed following AdIFN ad-
ministration were due to lupus exacerbation, similar
experiments were performed in male NZM mice, since
male mice do not develop lupus following IFN admin-
istration. Three weeks after AdIFN injection, 15-week-
old male NZM mice also exhibited significantly de-
creased endothelium-dependent vasorelaxation. As in
female NZM mice, AdIFN did not modify EPC num-
bers or apoptosis. In contrast to female NZM mice, male
mice did not display impaired EPC differentiation fol-
lowing AdIFN exposure (Figure 3B). These findings
indicate that most of the acute effects of IFN on the
vasculature are independent of lupus disease activity or
sex.
To assess whether the deleterious effects of IFN
on EC and EPC function are dependent on a lupus-
prone genetic background, AdIFN or AdControl was
administered to 12-week-old female BALB/c mice.
While these mice do not develop SLE upon exposure to
type I IFNs, they developed decreased endothelium-
dependent vasorelaxation and impaired EPC differenti-
ation (Figure 3C), with no modifications in EPC num-
bers or apoptosis (data not shown). These results
demonstrate that type I IFNs can promote endothelial
and EPC dysfunction independent of autoimmune back-
ground.
Modulation of plaque severity and arterial in-
flammation by type I IFNs in murine models of athero-
sclerosis. Endothelial dysfunction predicts plaque devel-
opment (11), and IFN can induce foam cell formation
in vitro (5). Further, myeloid IFN signaling promotes
Figure 2. Improved EPC function and in vivo neoangiogenesis in the
absence of type I interferon signaling in lupus-prone NZM mice.
A, Increased capacity of EPCs to differentiate into mature endothelial
cells (ECs) in female INZM mice at 20 weeks of age (left) and at 30
weeks of age (right) compared to age- and sex-matched NZM mice.
B, Significant improvement in BM EPC differentiation into mature
ECs in male INZM mice at 40 weeks of age. Values in A and B are the
mean SEM (n 6–8 mice per group in A and 9 mice per group in B).
  P  0.05 versus NZM mice. hpf  high-power field. C, Enhanced in
vivo neoangiogenesis in 25–30-week-old female and 30–40-week-old
male INZM mice compared to age- and sex-matched NZM mice, as
assessed by total mg hemoglobin (Hb) per gram of subcutaneous
Matrigel plug. Values are the mean  SEM (n  16 female mice per
group and 14 male mice per group).   P  0.05 versus NZM mice.
D, Representative images of Matrigel plugs demonstrating increased
numbers of von Willebrand factor (vWF)–positive ECs in 25–30-week-
old female INZM mice compared to age- and sex-matched NZM mice
(n  3 mice per group). There was an 7-fold increase in vWF-
positive cells in female INZM mice compared to those of female NZM
mice, when adjusted for DAPI-positive cells. Bar  200 m; original
magnification  40. See Figure 1 for other definitions.
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atherosclerosis by stimulating macrophage recruitment
to arteries (7). Since NZB  NZW and NZM mice
are resistant to developing florid diet-induced athero-
sclerosis, we investigated whether IFN directly affected
plaque severity in vivo in atherosclerosis-prone apoE/
mice (32). This was tested by exposing mice to acute
AdIFN infection at the time of Western diet initi-
ation, and through genetic abrogation of type I IFN
signaling (apoE/IFNAR/). There were no signifi-
cant differences in atherosclerosis severity between male
and female mice at the various time points examined.
After 10 weeks on a Western diet, female and male
apoE/IFNAR/ mice (18–20 weeks old) showed
significantly reduced atherosclerotic lesion size when
compared to age- and sex-matched apoE/ mice (Fig-
ures 4A and B). Additionally, there was a close to
significant trend toward larger atherosclerotic lesions in
apoE/ mice receiving AdIFN compared to apoE/
mice receiving AdControl (P  0.0604) (Figure 4A).
Aortic valve sections were stained with
macrophage- and T cell–specific antibodies. Less severe
atherosclerosis in apoE/IFNAR/ mice was asso-
ciated with significant decreases in macrophage and
T cell vasculature infiltration compared to apoE/mice
(Figure 4C). (Additional results are available online at
http://deepblue.lib.umich.edu/.) These findings indicate
that type I IFNs modulate atherosclerosis severity
and arterial inflammatory infiltrates. Aberrant vascular
repair may play a role in atherosclerosis development
in apoE/ mice (33). Compared to apoE/ mice,
apoE/IFNAR/ mice displayed increased angio-
genic capacity, as determined by an in vivo Matrigel
plug assay, and increased numbers of arterial wall
EPCs (Figure 5). These results indicate that lack of type
I IFN signaling promotes enhanced neoangiogenesis in
atherosclerosis-prone mice.
Type I IFNs may modulate HDL oxidation in
murine lupus. HDL oxidation renders the lipoprotein
dysfunctional and proinflammatory and may contribute
to atherogenesis. Lupus patients have increased plasma
levels of oxidized HDL (34,35). Previous work showed
that HDL nitrotyrosine content, a specific oxidative
process mediated by reactive nitrogen species, is ele-
vated in humans with established CVD (26). To assess
the contribution of type I IFNs to HDL nitration, HDL
was isolated from murine plasma and its nitrotyrosine
content was quantified. Thirty-week-old female NZM
mice had notable elevations in HDL nitrotyrosine con-
tent compared with age- and sex-matched BALB/c mice,
and this increase was abrogated in female INZM mice.
In contrast, AdIFN administration did not significantly
affect HDL nitrotyrosine content in NZM, apoE/, or
BALB/c mice (Figure 5). Significant differences in HDL
nitrotyrosine content were not observed between
apoE/IFNAR/ mice and apoE/ mice (mean 
SEM 688  83 versus 613  70 moles/mole tyrosine;
n  5–8 samples per group).
Modulation of thrombosis and platelet activation
by type I IFNs in murine models of lupus and athero-
sclerosis. Atheroma formation with superimposed
thrombosis represents the pathophysiologic process in
Figure 3. Impairment of endothelium-dependent vasorelaxation and
EPC function in lupus-prone and non–lupus-prone mice after acute
exposure to interferon- (IFN). A, Decreased endothelium-dependent
vasorelaxation (left) and reduced EPC differentiation (right) 3 weeks
postinjection in female NZM mice exposed to adenovirus IFN
(AdIFN) at 12 weeks of age, compared to age- and sex-matched
NZM mice exposed to adenovirus control (AdControl). B, Decreased
endothelium-dependent vasorelaxation (left) and unaltered EPC func-
tion (right) in male NZM mice exposed to AdIFN compared to mice
exposed to AdControl. C, Decreased endothelium-dependent vaso-
relaxation (left) and reduced EPC differentiation (right) 3 weeks
postinjection in female non–lupus-prone BALB/c mice exposed to
AdIFN at 12 weeks of age. Values are the mean  SEM (n  10–11
mice per group in A, 5–8 mice per group in B, and 12 mice per group
in C).  P 0.05;  P 0.01, versus mice exposed to AdControl.
ECs endothelial cells; hpf high-power field (see Figure 1 for other
definitions).
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acute coronary syndromes (ACS). SLE patients are at
increased risk of thrombotic events, and this phenome-
non may be multifactorial. Type I IFNs can affect the
megakaryocyte transcriptome and induce platelet acti-
vation in vitro (6). To address whether type I IFNs
promote a prothrombotic environment in vivo, a model
of carotid clot induction following photochemical injury
was used. After AdIFN exposure, apoE/ and NZM
Figure 4. Atherosclerosis severity and inflammatory arterial infiltra-
tion are sensitive to perturbations in type I interferon (IFN) signaling
in apoE/ mice. A, Significantly reduced atherosclerotic lesion size
in 18–20-week-old apoE/IFNAR/ mice compared to age- and
sex-matched apoE/ mice (n 13 mice per group). No differences in
atherosclerosis severity were observed between female and male mice
(n  9 mice per group). The apoE/ mice that received adenovirus
IFN (AdIFN) at 12 weeks of age displayed a trend toward increased
lesion size at 20 weeks of age (n  13 mice per group). Values are
the mean  SEM.   P  0.05. B, Representative en face views
of oil red O–stained aortic trees from an apoE/ mouse and an
apoE/IFNAR/ mouse, demonstrating decreased lesion size in
apoE/ mice lacking type I IFN receptor. The percentages of
atherosclerotic lesions in these representative images were 25.8%
for the apoE/ mouse and 14.1% for the apoE/IFNAR/
mouse. Original magnification  10. C, Significantly reduced macro-
phage and T cell infiltration of aortic valves in 18–20-week-old
apoE/IFNAR/ double-knockout (KO) mice compared to
apoE/ knockout mice. Values are the mean  SEM percent of area
infiltrated by macrophages or T cells, after counting 6 random fields
(n  6 mice per group).
Figure 5. Modulation of neoangiogenesis and high-density lipopro-
tein (HDL) oxidation by type I interferon (IFN) signaling. A and
B, Representative images (A) and quantification (B) of cells costaining
for Sca-1 and CD31 in the aortic roots of apoE/IFNAR/ and
apoE/ mice. Sca-1 staining was graded according to intensity on a
0–2 scale, where 0  no staining and 2  maximum intensity
staining. Cells showing maximum intensity staining were counted in
3 different representative fields per slide. In A, the boxed area shows a
higher-magnification view of the outlined region, displaying Sca-1
CD31 cells in the apoE/IFNAR/ mouse. Original magnifica-
tion  400. Values in B are the mean  SEM number of double-
positive cells (n  5 mice per group). C, Increased neoangiogenesis in
20–26-week-old apoE/IFNAR/ mice compared to age- and sex-
matched apoE/ mice. Neoangiogenesis was assessed as mg hemo-
globin (Hb) per gram Matrigel plug. Values are the mean SEM (n
11 mice per group).   P  0.05 versus apoE/ mice. D, Increased
levels of proinflammatory HDL, which decrease significantly in the
absence of type I IFN signaling, in 30-week-old female lupus-prone
NZM mice. Values are the mean  SEM micromoles HDL nitro-
tyrosine per mole tyrosine (n  8–10 mice per group).   P  0.01.
See Figure 1 for other definitions.
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mice displayed significantly shorter time to occlusive
thrombosis in the mid common carotid artery compared
to AdControl-treated mice (Figure 6A). In contrast, no
significant differences were observed with regard to time
to occlusive thrombosis between apoE/ mice and
apoE/IFNAR/ mice or between NZM mice and
INZM mice (mean  SEM 29.1  2.3 versus 31.2  3.2
minutes and 20  2.4 versus 26.2  4.6 minutes,
respectively).
Accelerated thrombosis in AdIFN-treated
apoE/ mice and NZM mice was associated with
enhanced endothelial and platelet activation, assessed
by serum P-selectin levels. Similar increases in soluble
P-selectin levels following AdIFN exposure were de-
tected in female BALB/c mice (Figure 6B). Compared
to age- and sex-matched NZM mice, soluble P-selectin
levels were decreased in 30-week-old female INZM mice
(Figure 6C). Administration of AdIFN to apoE/
mice and NZM mice resulted in enhanced platelet
P-selectin levels and an increased percentage of
leukocyte–platelet aggregates. Conversely, INZM mice
had significant decreases in the percentage of leukocyte–
platelet aggregates compared to NZM mice (Figure
6D). Compared to apoE/ mice, apoE/IFNAR/
mice exhibited a decreased percentage of leukocyte–
platelet aggregates (Figure 6E) but no significant
changes in platelet P-selectin levels (data not shown).
These results demonstrate that type I IFNs accelerate
thrombosis and induce platelet activation in murine
models of lupus and atherosclerosis.
DISCUSSION
Broad activation of type I IFN pathways in SLE
may play crucial roles in disease pathogenesis and
clinical manifestations (36). Recently, in vitro work from
several groups has suggested a putative link between
type I IFNs, vascular damage, and atherosclerosis pro-
gression in SLE (4–6). However, whether these effects
contribute significantly to endothelial dysfunction in vivo
had not been determined.
Our observations suggest that type I IFNs have
notable pleiotropic effects on the vasculature, from early
EC damage and aberrant vascular repair, to plaque
development and destabilization, followed by develop-
ment of ACS through thrombosis enhancement. We
show that type I IFNs play a direct, important role in CV
damage and endothelial dysfunction development in
vivo in lupus-prone mice and atheroma-prone mice, as
well as in mouse strains not typically associated with
lupus or enhanced atherothrombotic risk.
The nomenclature for vascular progenitor cells is
undergoing constant revision. For the purposes of this
work, we continue to refer to these cells as EPCs. IFN
is toxic to BM and blood EPCs in vitro (4,8), and
impairments in their phenotype and function may pro-
Figure 6. Modulation of thrombosis, endothelial activation, and
platelet activation by type I interferons (IFNs) in atherosclerosis-prone
and lupus-prone mice. A, Significantly shorter time to occlusive
thrombosis in the mid common carotid artery in 10–14-week-old
apoE/ and NZM mice exposed to adenovirus IFN (AdIFN)
compared to age- and sex-matched mice exposed to AdControl (n 
10–14 mice per group). Lack of type I IFN signaling in these mice
(20–22 weeks old) had no effect on time to occlusive thrombosis (n 
10–14 mice per group).   P  0.01 versus mice exposed to
AdControl. B, Correlation of shorter time to occlusive thrombosis with
increased serum soluble P-selectin (sP-selectin) levels in 10–11-week-
old apoE/ mice (n  8 mice per group) and 14-week-old NZM mice
(n 6 mice per group). AdIFN also increased serum P-selectin levels
in 17-week-old BALB/c mice (n  6 mice per group).   P  0.05.
C, Significantly decreased serum P-selectin levels in 30-week-old
INZM mice compared to NZM mice (n  10–15 mice per group).
  P  0.01 versus NZM mice. D, Modulation of platelet activation
by type I IFNs, as assessed by P-selectin expression on platelets (n 
9–10 mice per group) (left) and the percentage of leukocyte–platelet
aggregates (n 11–16 mice per group) (right) in 20–25-week old mice.
  P  0.05 versus wild-type mice or mice exposed to AdControl.
Values are the mean  SEM. See Figure 1 for other definitions.
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mote the endothelial dysfunction that has been reported
in murine and human lupus (10,13). While endothelial
function and EPC numbers are reduced and functionally
impaired in chronic kidney disease (37), the modulation
of endothelial and EPC function by type I IFNs appears
to be independent of renal dysfunction or of other
immune abnormalities characteristic of SLE. Indeed,
male NZM mice, spared from overt lupus development
and glomerulonephritis, still exhibit significant differ-
ences in vascular parameters when compared to male
INZM mice. This is consistent with the results of previ-
ous studies of human EPCs/circulating angiogenic cells,
where lupus disease activity did not explain the profound
vascular phenotypic and functional abnormalities (4).
These observations support a specific role for type I
IFNs in endothelial dysfunction and loss of EPC num-
bers and function in vivo.
Our findings indicate that chronic and enhanced
exposure to type I IFNs may be needed to induce
significant decreases in EPC numbers in vivo, since
acute exposure to IFN did not lead to alterations in
these parameters, although it significantly impaired EPC
differentiation. It is also possible that these effects on
the vasculature are mediated, at least in part, by other
IFNs besides IFN, since the knockout system used in
this study deleted signaling by all type I IFNs (14,15).
Indeed, while the differential effects that various type I
IFNs play in the vasculature and in endothelial repair
remain unclear, recent evidence suggests a role for type
I IFNs other than IFN in antiangiogenic responses and
atherosclerosis modulation (7,38).
Type I IFNs can impair the ability of stem cells to
repopulate the BM niche. Therefore, the negative im-
pact of IFNs on EPC function could indicate a more
general stem cell impairment (39). Furthermore, type I
IFNs can induce apoptosis and senescence of mature
ECs (40). Therefore, long-term exposure to type I IFNs,
as is observed in SLE, could promote sustained vascular
damage and reduced local repair, leading to enhanced
EPC and mature EC consumption, as shown in athero-
sclerosis models (33). Impaired EPC differentiation by
type I IFNs may be associated with induction of anti-
angiogenic signatures in these cells and in other tissue,
as we previously described in human lupus in vivo (8).
This could create a cytokine profile that enhances
antiangiogenic responses, promotes vasculopathy, and
accelerates atherosclerosis.
Lupus-prone mice are resistant to florid diet-
induced atherosclerosis, unless crossed with proathero-
sclerotic models (41–44), or used to generate chimeras
following lupus BM transplantation into atherosclerosis-
prone mice (45). While those studies demonstrated that
lupus immune dysregulation accelerates plaque develop-
ment, they have not addressed the specific roles of type
I IFNs and have been performed primarily in murine
models that do not appear to depend on these cytokines
for disease progression (46,47).
Recent evidence points to a potentially crucial
role for type I IFNs in atherosclerosis due to the ability
of IFN to increase foam cell formation (5), its in-
creased expression in areas of unstable human arterial
plaques (48), and the capacity of myeloid IFN to
worsen atherosclerosis (7). Strong associations of type I
IFN signatures in human SLE with impaired peripheral
arterial tone (49) and carotid intima-media thickness
have been found (50). In the present study, we present
direct in vivo evidence that type I IFNs significantly
modulate plaque development and the severity of arte-
rial macrophage and T cell infiltration in atherosclerosis-
prone murine systems. Under proatherogenic conditions,
monocytes migrate to vessel walls and differentiate into
macrophages that can become lipid-laden foam cells.
The biologic properties of atherosclerotic plaque macro-
phages and T lymphocytes determine lesion size, com-
position, and stability (45,51). Decreased macrophage
infiltration in apoE/IFNAR/ mice may be second-
ary to impaired monocyte recruitment and/or differen-
tiation into foam cells, as supported by recent observa-
tions (7,52).
The proatherogenic effects of type I IFNs may
be partially mediated by deleterious modulation of lipo-
proteins. While HDL is atheroprotective through roles
in reverse cholesterol transport and antiinflammatory
properties, it may become proinflammatory and pro-
mote atherothrombosis (26). SLE patients have in-
creased proinflammatory HDL (34,35), an abnormality
we have now observed in female NZM mice. While
oxidized HDL levels were decreased in female INZM
mice, we could not elucidate if this was due to abroga-
tion of type I IFN signaling on lipoprotein oxidation, or
related to lack of lupus development in these mice. Since
male NZM mice do not develop increased oxidized
HDL, we used these mice as a reliable comparison.
Furthermore, AdIFN administration did not increase
HDL oxidation, even if it exacerbated lupus. It is
possible that chronic, rather than acute, differences in
type I IFN signaling are required for lipoprotein dys-
regulation. Nevertheless, our results suggest a putative
role of these cytokines in lipoprotein oxidation and the
redox environment in vivo, which requires further inves-
tigation.
While platelets are activated in SLE and display
evidence of increased exposure to type I IFNs (6), the
functional relevance of this phenomenon in vivo had
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not previously been addressed. In our study, NZM and
apoE/ mice exposed to IFN had a shorter time to
occlusive thrombosis upon photochemical injury. This
was associated with enhanced platelet activation, inde-
pendent of a lupus-prone genetic background. Since
circulating activated platelets can exacerbate atheroscle-
rosis in murine systems (53), it is possible that this type
I IFN–induced phenomenon also contributed to plaque
formation. Future studies should address how type I
IFNs modulate endothelial and platelet activation in
autoimmune and nonautoimmune backgrounds, and the
interplay of these molecules with lipoproteins and other
factors. Furthermore, our results shed light on previous
reports that infections may precede or be associated with
enhanced atherothrombotic risk (54,55). Indeed, this
may be mediated via type I IFNs, following exposure to
microbial products (48).
The results of the present study also support the
notion that treatments disrupting type I IFN signaling,
which are currently being tested in various autoimmune
diseases, could promote additional benefits by hamper-
ing CV risk. Therefore, it will be important to include
biomarkers of vascular damage and functional studies of
endothelial health as end points of efficacy analyses for
patients receiving these agents. Whether inhibition of
these pathways in the general population would also
decrease atherosclerosis progression should be investi-
gated.
ACKNOWLEDGMENTS
We thank Dr. Chaim Jacob for providing breeding
pairs of NZM2328 and NZM2328 IFNR/ mice and Dr.
Herbert W. Virgin for providing breeding pairs of IFNR/
mice.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Kaplan had full access to all of
the data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Study conception and design. Thacker, Koch, Pennathur, Davidson,
Eitzman, Kaplan.
Acquisition of data. Thacker, Zhao, Smith, Luo, Wang, Vivekanandan-
Giri, Rabquer, Pennathur.
Analysis and interpretation of data. Thacker, Smith, Luo,
Vivekanandan-Giri, Rabquer, Koch, Pennathur, Eitzman, Kaplan.
REFERENCES
1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla
P, et al. Morbidity and mortality in systemic lupus erythematosus
during a 10-year period: a comparison of early and late manifes-
tations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;
82:299–308.
2. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du
Berger R, et al. Traditional Framingham risk factors fail to fully
account for accelerated atherosclerosis in systemic lupus erythem-
atosus. Arthritis Rheum 2001;44:2331–7.
3. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr,
Jansen-McWilliams L, et al. Age-specific incidence rates of myo-
cardial infarction and angina in women with systemic lupus
erythematosus: comparison with the Framingham Study. Am J
Epidemiol 1997;145:408–15.
4. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ,
et al. Interferon- promotes abnormal vasculogenesis in lupus: a
potential pathway for premature atherosclerosis. Blood 2007;110:
2907–15.
5. Li J, Fu Q, Cui H, Qu B, Pan W, Shen N, et al. Interferon-
priming promotes lipid uptake and macrophage-derived foam cell
formation: a novel link between interferon- and atherosclerosis
in lupus. Arthritis Rheum 2011;63:492–502.
6. Lood C, Amisten S, Gullstrand B, Jonsen A, Allhorn M,
Truedsson L, et al. Platelet transcriptional profile and protein
expression in patients with systemic lupus erythematosus: up-
regulation of the type I interferon system is strongly associated
with vascular disease. Blood 2010;116:1951–7.
7. Goossens P, Gijbels MJ, Zernecke A, Eijgelaar W, Vergouwe MN,
van der Made I, et al. Myeloid type I interferon signaling promotes
atherosclerosis by stimulating macrophage recruitment to lesions.
Cell Metab 2010;12:142–53.
8. Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M,
Kaplan MJ. The detrimental effects of IFN- on vasculogenesis in
lupus are mediated by repression of IL-1 pathways: potential role
in atherogenesis and renal vascular rarefaction. J Immunol 2010;
185:4457–69.
9. Banchereau J, Pascual V. Type I interferon in systemic lupus
erythematosus and other autoimmune diseases. Immunity 2006;
25:383–92.
10. Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D,
Lewis E, et al. Endothelial cell apoptosis in systemic lupus
erythematosus: a common pathway for abnormal vascular function
and thrombosis propensity. Blood 2004;103:3677–83.
11. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Dela-
grange D, Creager MA, et al. Systemic nature of endothelial
dysfunction in atherosclerosis. Am J Cardiol 1995;75:71B–4B.
12. Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA,
et al. Recipes for creating animal models of diabetic cardiovascu-
lar disease. Circ Res 2007;100:1415–27.
13. Thacker SG, Duquaine D, Park J, Kaplan MJ. Lupus-prone New
Zealand Black/New Zealand White F1 mice display endothelial
dysfunction and abnormal phenotype and function of endothelial
progenitor cells. Lupus 2010;19:288–99.
14. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H,
Kamijo R, et al. Immune response in mice that lack the interfer-
on- receptor. Science 1993;259:1742–5.
15. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel
RM, et al. Functional role of type I and type II interferons in
antiviral defense. Science 1994;264:1918–21.
16. Ramanujam M, Kahn P, Huang W, Tao H, Madaio MP, Factor
SM, et al. Interferon- treatment of female (NZW  BXSB)F1
mice mimics some but not all features associated with the Yaa
mutation. Arthritis Rheum 2009;60:1096–101.
17. Nacionales DC, Kelly-Scumpia KM, Lee PY, Weinstein JS, Lyons
R, Sobel E, et al. Deficiency of the type I interferon receptor
protects mice from experimental lupus. Arthritis Rheum 2007;56:
3770–83.
18. Zhao W, Thacker SG, Hodgin JB, Zhang H, Wang JH, Park JL,
et al. The peroxisome proliferator-activated receptor  agonist
2984 THACKER ET AL
pioglitazone improves cardiometabolic risk and renal inflamma-
tion in murine lupus. J Immunol 2009;183:2729–40.
19. Chakroborty D, Chowdhury UR, Sarkar C, Baral R, Dasgupta PS,
Basu S. Dopamine regulates endothelial progenitor cell mobiliza-
tion from mouse bone marrow in tumor vascularization. J Clin
Invest 2008;118:1380–9.
20. Silverman MD, Haas CS, Rad AM, Arbab AS, Koch AE. The role
of vascular cell adhesion molecule 1/ very late activation antigen 4
in endothelial progenitor cell recruitment to rheumatoid arthritis
synovium. Arthritis Rheum 2007;56:1817–26.
21. Rabquer BJ, Amin MA, Teegala N, Shaheen MK, Tsou PS, Ruth
JH, et al. Junctional adhesion molecule-C is a soluble mediator of
angiogenesis. J Immunol 2010;185:1777–85.
22. Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch
AE. Migration inhibitory factor mediates angiogenesis via mito-
gen-activated protein kinase and phosphatidylinositol kinase. Circ
Res 2003;93:321–9.
23. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen
activator inhibitor-1 and vitronectin promote vascular thrombosis
in mice. Blood 2000;95:577–80.
24. Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM, Eitzman DT.
Recombinant leptin promotes atherosclerosis and thrombosis in
apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol
2005;25:e119–22.
25. McPherson PA, Young IS, McKibben B, McEneny J. High density
lipoprotein subfractions: isolation, composition, and their duplic-
itous role in oxidation. J Lipid Res 2007;48:86–95.
26. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, Singh P, et al.
Human atherosclerotic intima and blood of patients with estab-
lished coronary artery disease contain high density lipoprotein
damaged by reactive nitrogen species. J Biol Chem 2004;279:
42977–83.
27. Vivekanandan-Giri A, Byun J, Pennathur S. Quantitative analysis
of amino Acid oxidation markers by tandem mass spectrometry.
Methods Enzymol 2011;491:73–89.
28. Waters ST, Fu SM, Gaskin F, Deshmukh US, Sung SS, Kannapell
CC, et al. NZM2328: a new mouse model of systemic lupus
erythematosus with unique genetic susceptibility loci. Clin Immu-
nol 2001;100:372–83.
29. Malyszko J. Mechanism of endothelial dysfunction in chronic
kidney disease. Clin Chim Acta 2010;411:1412–20.
30. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME,
Julkunen I, et al. Viral infection and Toll-like receptor agonists
induce a differential expression of type I and  interferons in
human plasmacytoid and monocyte-derived dendritic cells. Eur
J Immunol 2004;34:796–805.
31. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G,
Vallin H, et al. Activation of type I interferon system in systemic
lupus erythematosus correlates with disease activity but not with
antiretroviral antibodies. Lupus 2000;9:664–71.
32. Bentzon JF, Falk E. Atherosclerotic lesions in mouse and man: is
it the same disease? Curr Opin Lipidol 2010;21:434–40.
33. Zhu S, Liu X, Li Y, Goldschmidt-Clermont PJ, Dong C. Aging in
the atherosclerosis milieu may accelerate the consumption of bone
marrow endothelial progenitor cells. Arterioscler Thromb Vasc
Biol 2007;27:113–9.
34. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace
DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as
a biomarker for atherosclerosis in patients with systemic lupus
erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:
2541–9.
35. McMahon M, Grossman J, Skaggs B, FitzGerald J, Sahakian L,
Ragavendra N, et al. Dysfunctional proinflammatory high-density
lipoproteins confer increased risk of atherosclerosis in women with
systemic lupus erythematosus. Arthritis Rheum 2009;60:2428–37.
36. Crow MK. Interferon-: a therapeutic target in systemic lupus
erythematosus. Rheum Dis Clin North Am 2010;36:173–86.
37. Bahlmann FH, Speer T, Fliser D. Endothelial progenitor cells in
chronic kidney disease. Nephrol Dial Transplant 2010;25:341–6.
38. Taylor KL, Leaman DW, Grane R, Mechti N, Borden EC, Lindner
DJ. Identification of interferon--stimulated genes that inhibit
angiogenesis in vitro. J Interferon Cytokine Res 2008;28:733–40.
39. Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon
regulatory factor-2 protects quiescent hematopoietic stem cells
from type I interferon-dependent exhaustion. Nat Med 2009;15:
696–700.
40. Kaiser WJ, Kaufman JL, Offermann MK. IFN- sensitizes human
umbilical vein endothelial cells to apoptosis induced by double-
stranded RNA. J Immunol 2004;172:1699–710.
41. Aprahamian T, Rifkin I, Bonegio R, Hugel B, Freyssinet JM, Sato
K, et al. Impaired clearance of apoptotic cells promotes synergy
between atherogenesis and autoimmune disease. J Exp Med
2004;199:1121–31.
42. Feng X, Li H, Rumbin AA, Wang X, La Cava A, Brechtelsbauer
K, et al. ApoE/Fas/ C57BL/6 mice: a novel murine model
simultaneously exhibits lupus nephritis, atherosclerosis, and os-
teopenia. J Lipid Res 2007;48:794–805.
43. Ma Z, Choudhury A, Kang SA, Monestier M, Cohen PL, Eisen-
berg RA. Accelerated atherosclerosis in ApoE deficient lupus
mouse models. Clin Immunol 2008;127:168–75.
44. Stanic AK, Stein CM, Morgan AC, Fazio S, Linton MF, Wakeland
EK, et al. Immune dysregulation accelerates atherosclerosis and
modulates plaque composition in systemic lupus erythematosus.
Proc Natl Acad Sci U S A 2006;103:7018–23.
45. Gautier EL, Huby T, Ouzilleau B, Doucet C, Saint-Charles F,
Gremy G, et al. Enhanced immune system activation and arterial
inflammation accelerates atherosclerosis in lupus-prone mice.
Arterioscler Thromb Vasc Biol 2007;27:1625–31.
46. Hron JD, Peng SL. Type I IFN protects against murine lupus.
J Immunol 2004;173:2134–42.
47. Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner
W, et al. Interferon-: a therapeutic for autoimmune lupus in
MRL-Faslpr mice. J Am Soc Nephrol 2005;16:3264–72.
48. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL,
Weyand CM. Synergistic proinflammatory effects of the antiviral
cytokine interferon- and Toll-like receptor 4 ligands in the
atherosclerotic plaque. Circulation 2007;116:2043–52.
49. Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, et al.
Type I interferon as a novel risk factor for endothelial progenitor
cell depletion and endothelial dysfunction in systemic lupus ery-
thematosus. Arthritis Rheum 2007;56:3759–69.
50. Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B,
et al. Type I interferons are associated with subclinical markers of
cardiovascular disease in a cohort of systemic lupus erythematosus
patients. PLoS One 2012;7:e37000.
51. Ye D, Zhao Y, Hildebrand RB, Singaraja RR, Hayden MR, Van
Berkel TJ, et al. The dynamics of macrophage infiltration into the
arterial wall during atherosclerotic lesion development in low-
density lipoprotein receptor knockout mice. Am J Pathol 2011;
178:413–22.
52. Lee PY, Li Y, Kumagai Y, Xu Y, Weinstein JS, Kellner ES, et al.
Type I interferon modulates monocyte recruitment and matura-
tion in chronic inflammation. Am J Pathol 2009;175:2023–33.
53. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, et
al. Circulating activated platelets exacerbate atherosclerosis in
mice deficient in apolipoprotein E. Nat Med 2003;9:61–7.
54. Zurru MC, Alonzo C, Brescacin L, Romano M, Camera LA,
Waisman G, et al. Recent respiratory infection predicts athero-
thrombotic stroke: case–control study in a Buenos Aires health-
care system. Stroke 2009;40:1986–90.
55. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P,
Vallance P. Risk of myocardial infarction and stroke after acute
infection or vaccination. N Engl J Med 2004;351:2611–8.
TYPE I IFNs AND VASCULAR DAMAGE IN MURINE LUPUS 2985
